MacroGenics Inc.'s positive Phase III SOPHIA study sets its margetuximab up for a role in treating third-line-plus HER2-positive metastatic breast cancer (mBC) with potential to expand to earlier lines and other cancers. It also bodes well for the company's antibody engineering platform.
MacroGenics reported on Feb. 6, to great fanfare, positive progression-free survival (PFS) data in SOPHIA, which tested margetuximab with chemo versus Roche's pioneering HER2 therapy Herceptin (trastuzumab) with chemo...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?